NASDAQ:NRXS NeurAxis (NRXS) Stock Price, News & Analysis → $1,500 to $9,400 in one month? (A.I. Trade List) (From Prosper Trading Academy) (Ad) Free NRXS Stock Alerts $3.16 +0.13 (+4.29%) (As of 05/24/2024 ET) Add Compare Share Share Today's Range$3.04▼$3.2650-Day Range$2.76▼$3.5952-Week Range$1.80▼$6.93Volume5,643 shsAverage Volume9,563 shsMarket Capitalization$21.01 millionP/E RatioN/ADividend YieldN/APrice TargetN/A Stock AnalysisStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesOwnershipSEC FilingsTrendsStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesOwnershipSEC FilingsTrends Get NeurAxis alerts: Email Address Ad Porter & CompanyMusk, Bezos, and Gates All On Board… Sam Altman, the CEO of OpenAI, has invested $375 million into a breakthrough technology, that legendary financial analyst Porter Stansberry believes… …could be the number-one investment of the decade.To get all the details of this controversial tech – click here now. About NeurAxis Stock (NASDAQ:NRXS)NeurAxis, Inc., a medical technology company, focuses on developing neuromodulation therapies to address chronic and debilitating conditions in children and adults in the United States. It offers IB-Stim, a percutaneous electrical nerve field stimulation system intended to be used in patients 11-18 years of age with functional abdominal pain associated with irritable bowel syndrome. The company sells its products to healthcare companies, including hospitals and clinics. The company was formerly known as Innovative Health Solutions, Inc. and changed its name to NeurAxis, Inc. in March 2022. The company was founded in 2011 and is headquartered in Carmel, Indiana.Read More NRXS Stock Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart NRXS Stock News HeadlinesMay 24 at 12:59 PM | msn.comNeurAxis, Inc. (NASDAQ:NRXS) Q1 2024 Earnings Call TranscriptMay 24 at 6:16 AM | americanbankingnews.comFc Global Realty (OTCMKTS:FCRE) versus NeurAxis (NASDAQ:NRXS) Critical ReviewMay 23 at 1:20 AM | americanbankingnews.comReviewing NeurAxis (NASDAQ:NRXS) and Outset Medical (NASDAQ:OM)May 22, 2024 | finanznachrichten.deNeurAxis, Inc.: NeurAxis Reports First Quarter 2024 Financial ResultsMay 22, 2024 | msn.comNeurAxis GAAP EPS of -$0.32, revenue of $0.65MMay 22, 2024 | globenewswire.comNeurAxis Reports First Quarter 2024 Financial ResultsMay 21, 2024 | globenewswire.comNeurAxis to Participate in the Lytham Partners Spring 2024 Investor Conference on May 30, 2024May 19, 2024 | americanbankingnews.comAnalyzing NeurAxis (NRXS) and Its CompetitorsMay 18, 2024 | americanbankingnews.comHead to Head Comparison: NeurAxis (NRXS) and Its CompetitorsMay 17, 2024 | americanbankingnews.comHead to Head Comparison: NeurAxis (NRXS) and Its PeersMay 17, 2024 | americanbankingnews.comReviewing NeurAxis (NRXS) and Its RivalsMay 17, 2024 | americanbankingnews.comHead to Head Analysis: NeurAxis (NRXS) vs. Its CompetitorsMay 16, 2024 | finance.yahoo.comNeurAxis Announces New Medical Policy Coverage For Nearly Six Million Lives in FloridaMay 15, 2024 | globenewswire.comNeurAxis to Host First Quarter 2024 Results and Business Update Call on Wednesday, May 22, 2024April 23, 2024 | globenewswire.comNeurAxis Announces New Medical Policy Coverage in North DakotaApril 12, 2024 | finance.yahoo.comNeurAxis, Inc. (NASDAQ:NRXS) Q4 2023 Earnings Call TranscriptApril 11, 2024 | finanznachrichten.deNeurAxis, Inc.: NeurAxis Reports Fourth Quarter and Fiscal Year 2023 Financial ResultsApril 11, 2024 | seekingalpha.comNeurAxis, Inc. (NRXS) Q4 2023 Earnings Call TranscriptApril 9, 2024 | globenewswire.comNeurAxis Reports Fourth Quarter and Fiscal Year 2023 Financial ResultsApril 1, 2024 | globenewswire.comNeurAxis to Host Fourth Quarter and Full Year 2023 Results and Business Update Call on Tuesday, April 9, 2024March 27, 2024 | globenewswire.comNeurAxis Announces IB-Stim Results from a Large, Pediatric, Multi-Center RegistryMarch 11, 2024 | globenewswire.comNeurAxis Announces Highmark BCBS Policy CoverageMarch 4, 2024 | globenewswire.comNeurAxis Announces Blue Cross and Blue Shield of Kansas City Policy CoverageFebruary 27, 2024 | globenewswire.comNeurAxis to Present at Oppenheimer 34th Annual Healthcare MedTech & Services ConferenceFebruary 1, 2024 | au.finance.yahoo.comNeurAxis, Inc. (NRXS)See More Headlines Receive NRXS Stock News and Ratings via Email Sign-up to receive the latest news and ratings for NeurAxis and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Last Earnings4/16/2024Today5/26/2024Fiscal Year End12/31/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Electromedical equipment Sub-IndustryN/A Current SymbolNASDAQ:NRXS CUSIPN/A CIK1933567 Webneuraxis.com Phone(812) 689-0791FaxN/AEmployees19Year FoundedN/AProfitability EPS (Most Recent Fiscal Year)($3.73) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-14,630,000.00 Net Margins-633.10% Pretax Margin-633.15% Return on EquityN/A Return on Assets-926.02% Debt Debt-to-Equity RatioN/A Current Ratio0.11 Quick Ratio0.12 Sales & Book Value Annual Sales$2.46 million Price / Sales8.54 Cash FlowN/A Price / Cash FlowN/A Book Value($0.48) per share Price / Book-6.58Miscellaneous Outstanding Shares6,650,000Free FloatN/AMarket Cap$21.01 million OptionableNot Optionable BetaN/A 5G Stocks: The Path Forward is ProfitableClick the link below and we'll send you MarketBeat's guide to investing in 5G and which 5G stocks show the most promise. Get This Free Report Key ExecutivesMr. Brian Carrico (Age 42)President, CEO & Director Comp: $839.4kMr. Timothy Robert Henrichs (Age 51)Chief Financial Officer Comp: $23.84kDr. Adrian Miranda (Age 54)Senior VP of Science & Technology and Chief Medical Officer Comp: $323.05kDr. Thomas Carrico (Age 67)Chief Regulatory Officer and Compliance Officer & Privacy Officer Comp: $411.1kDr. Christopher Robin Brown D.D.S. (Age 70)Founder, Director of Innovation & Director Key CompetitorsBioSig TechnologiesNASDAQ:BSGMQT ImagingNASDAQ:QTIPixie Dust TechnologiesNASDAQ:PXDTPrecision OpticsNASDAQ:POCIelectroCoreNASDAQ:ECORView All Competitors NRXS Stock Analysis - Frequently Asked Questions Should I buy or sell NeurAxis stock right now? 1 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for NeurAxis in the last year. There are currently 1 buy rating for the stock. The consensus among Wall Street equities research analysts is that investors should "buy" NRXS shares. View NRXS analyst ratings or view top-rated stocks. How have NRXS shares performed in 2024? NeurAxis' stock was trading at $2.67 at the start of the year. Since then, NRXS shares have increased by 18.4% and is now trading at $3.16. View the best growth stocks for 2024 here. How were NeurAxis' earnings last quarter? NeurAxis, Inc. (NASDAQ:NRXS) posted its earnings results on Tuesday, April, 16th. The company reported $0.29 earnings per share for the quarter. The business had revenue of $0.53 million for the quarter. When did NeurAxis IPO? NeurAxis (NRXS) raised $7 million in an initial public offering (IPO) on Wednesday, August 9th 2023. The company issued 1,098,667 shares at $6.00 per share. How do I buy shares of NeurAxis? Shares of NRXS stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here. This page (NASDAQ:NRXS) was last updated on 5/26/2024 by MarketBeat.com Staff From Our Partners[FREE Ticket] 27 Crypto Experts Reveal Their #1 Picks Crypto 101 MediaClaim Your Complimentary Bitcoin RewardCrypto Swap Profits$1,500 to $9,400 in one month? (A.I. Trade List)Prosper Trading AcademyElon’s New Device is About to Shock the WorldInvestorPlaceNew Options need New Trading StrategiesNetpicksWrite this ticker symbol down…StocksToTradeElon to Transform U.S. Economy? Porter & CompanyBill Clinton Backing Biden Replacement???The Freeport Society Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding NeurAxis, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.